FN1 and cancer: However, while these studies and clinical evidence have explored specific cancer types based on limited sample sizes, there has yet to be a large-scale pan-cancer study focusing on alternative splicing characteristics of FN in the context of clinical diagnostics and prognostics to examine its potential as a targetable biomarker for molecular diagnostics and therapies.